XOMA Corp 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th XOMAO 深 滬
等待開盤 12-19 09:30:00 美东时间
25.59
+0.030
+0.12%
華盛通- 最 高25.59
- 今 開25.465
- 成交量 2038股
- 最 低 25.40
- 昨 收 25.56
- 總市值 4094.40万
- 52周最高 25.6258
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 22.2731
- 委 比 -62.14%
- 總股本 160.00万
- 歷史最高 25.59
- 量 比 0.28
- 振 幅 0.74%
- 歷史最低 14.5932
- 每 手 1
- 風險率 0.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多XOMA Royalty to acquire Generation Bio
XOMA Royalty (XOMA) has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share. Generation Bio stockholders also will receive one non-transferable contingent ...
12-16 06:28
Why Is XOMA Royalty Stock Sinking Thursday?
XOMA stock plunged after its partner Rezolute Inc. reported disappointing trial results for their product Ersodetug.
12-12 02:09
Academy Sports and Outdoors, Tronox, STAAR Surgical And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining more than 100 points on Tue...
12-10 01:00
Mural Oncology Announces Sanction of the Scheme by the High Court
Mural Oncology plc has announced that the High Court of Ireland has approved a scheme of arrangement under the Companies Act 2014. This scheme allows XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, to acquire 100% of Mural's shares. The acquisition is expected to become effective on December 5, 2025, after the court order is delivered to the Irish Registrar of Companies. Consequently, trading of Mural shares on Nasdaq will cease on Decembe...
12-03 21:30
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
Submits Recalculated Initial Offer of $4.75 Based on Board's Value Destructive Actions Nominated Two Independent Candidates to Restore Oversight and Protect Shareholders Urges Shareholders t...
12-03 07:48
Mural Oncology Shareholders To Receive $2.035 Per Share As XOMA Royalty Acquisition; Set To Close In Early December 2025
Mural Oncology plc (NASDAQ:MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), XRA 5 Corp. ("Sub") and Mural
11-26 22:03
XOMA Completes Acquisition of LAVA Therapeutics
Xoma ( ($XOMA) ) has issued an update. XOMA Royalty Corporation, a company invo...
11-21 21:29
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
XOMA Royalty has successfully acquired all outstanding shares of LAVA Therapeutics, paying $1.04 per share and offering a contingent value right (CVR) for potential future payments. The deal strengthens XOMA's portfolio with two early-stage bispecific antibodies in collaboration with Johnson & Johnson and Pfizer, aiming to drive long-term value. LAVA shareholders tendered approximately 91.1% of shares, leading to delisting and deregistration from...
11-21 12:45
LAVA intents to delist from Nasdaq
LAVA Therapeutics (LVTX) announced on Thursday that it has submitted written notice to Nasdaq of its intention to voluntarily delist its common shares from Nasdaq. The company also stated that 22.88M ...
11-13 21:51
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
LAVA Therapeutics N.V. has issued a reminder to its shareholders regarding the proposed acquisition by XOMA Royalty Corporation. The offer to purchase all outstanding common shares of LAVA has been extended until November 12, 2025. LAVA’s board unanimously recommends shareholders tender their shares before the expiration to avoid risks such as liquidation or significant stock price decline. Instructions for tendering shares via brokers or directl...
11-10 21:09
